Roche-Hansoh, Merck KGaA-Silence, and Lilly-METiS deals show how ADCs, siRNA, and lipid nanoparticles reshape demands on CMC and manufacturing teams.
News|Articles|February 1, 2002
- Pharmaceutical Technology-02-02-2002
- Volume 26
- Issue 2
Outsourcing Outlook
Author(s)Jim Miller
The author discusses current economic times and conditions for large pharmaceutical companies.
Advertisement
Articles in this issue
over 24 years ago
Using Earned-Value Analysis to Better Manage Projectsover 24 years ago
Microbial Bioburden on Oral Solid Dosage Formsover 24 years ago
Modernizing Pharmaceutical ManufacturingAdvertisement
Related to this article
Germany is home to several prominent pharma companies and more than 1000 innovative biotechs.
The company is showcasing new development solutions and advanced digital technologies including its new OSD Express and Steriles Express solutions for drug development.
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
MASH and Cardiomyopathy Targets: Why AstraZeneca Chose insitro’s AI
2
Germany’s Medical Biotechnology Sector is Flourishing
3
First-in-Human Trial Speed: Why FDA Trails China
4
Formulation Strategies for Next-Generation Multiagonists
5